NCT05155332 2026-04-14
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
Clinical Trials
7 trialsNCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06265727 2026-01-08
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06603844 2025-06-03
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05204862 2023-04-03
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
Phase 1/2 Recruiting